

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 265/18, A61K 31/535	A1	(11) International Publication Number: WO 94/03440 (43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: PCT/US93/07376 (22) International Filing Date: 6 August 1993 (06.08.93) (30) Priority data: 926,607 7 August 1992 (07.08.92) US 08/054,805 27 April 1993 (27.04.93) US (60) Parent Applications or Grants (63) Related by Continuation US 08/054,805 (CIP) Filed on 27 April 1993 (27.04.93) US 926,607 (CIP) Filed on 7 August 1992 (07.08.92) (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	(72) Inventors; and (75) Inventors/Applicants (for US only) : YOUNG, Steven, D. [US/US]; 1280 Mark Drive, Lansdale, PA 19446 (US). BRITCHER, Susan, F. [US/US]; 735 Port Indian Road, Norristown, PA 19403 (US). PAYNE, Linda, S. [US/US]; 1402 Henning Way, Lansdale, PA 19446 (US). TRAN, Lekhanh, O. [US/US]; 1126 Laurel Drive, West Chester, PA 19380 (US). LUMMA, William, C., Jr. [US/US]; 1447 Newman Road, Pennsburg, PA 18073 (US). (74) Agent: MEREDITH, Roy, D.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: BB, BG, BR, BY, CZ, FI, HU, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: BENZOXAZINONES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE



(57) Abstract

Certain benzoxazinones of formula (I), wherein: X is halo, X¹ is trihalomethyl, or pentahaloethyl, Z is O, are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

- 2 -

HIV, the treatment of infection by HIV and in the treatment of AIDS and/or ARC, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV are also disclosed.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

This invention is concerned with compounds of formula I, combinations thereof, or pharmaceutically acceptable salts thereof, in the inhibition of HIV reverse transcriptase and its resistant varieties, the prevention or treatment of infection by HIV and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). Compounds of formula I are defined as follows:



wherein:

X is halo,
X¹ is trihalomethyl, or pentahaloethyl;
Z is O;

R is

- (a) C₁₋₈ alkyl, unsubstituted or substituted with A, and A is halo, C₃₋₆ cycloalkyl, CN, hydroxy, C₁₋₄ alkoxy, C₂₋₄ alkynyl-C₁₋₄ alkoxy, aryloxy, C₁₋₄ alkylcarbonyl, nitro, di(C₁₋₂ alkyl)amino, C₁₋₄ alkylamino-C₁₋₂ alkyl, heterocycle, or arylthio;
- (b) C₂₋₄ alkenyl, unsubstituted or substituted with

SUBSTITUTE SHEET

- 1 -

TITLE OF THE INVENTION

BENZOXAZINONES AS INHIBITORS OF HIV REVERSE
TRANSCRIPTASE

5 BACKGROUND OF THE INVENTION

This case is related to Merck cases 18429, 18429IA and 18727. This case is a continuation-in-part of Merck Case 18793, filed August 7, 1992, U.S.S.N. 07/926,607.

10 A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus replication is
15 reverse transcription of the RNA genome by a virally encoded reverse transcriptase to generate DNA copies of HIV sequences, a required step in viral replication. It is known that some compounds are reverse transcriptase inhibitors and are effective agents in the treatment of AIDS and similar diseases, e.g., azidothymidine or AZT.

20 Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277 (1985)]. Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al.,
25 Science, 231, 1567 (1986); Pearl, L.H. et al., Nature 329, 351 (1987)].

Applicants demonstrate that the compounds of this invention are inhibitors of HIV reverse transcriptase. The particular advantages of the present compounds are their demonstrated inhibition
30 of resistant HIV reverse transcriptase.

BRIEF DESCRIPTION OF THE INVENTION


Compounds of formula I, as herein defined, are disclosed. These compounds are useful in the inhibition of HIV reverse transcriptase (and its resistant varieties), the prevention of infection by

- 3 -

- (i) A, or
 (ii) aryl, unsubstituted or substituted with A;
 (c) C₂₋₅ alkynyl, unsubstituted or substituted with
 (i) A, or
 (ii) aryl, unsubstituted or substituted with A; or
 (d) C₃₋₄ cycloalkyl, unsubstituted or substituted with
 (i) A, or
 (ii) aryl, unsubstituted or substituted with A,

or pharmaceutically acceptable salt thereof.

This invention also encompasses a pharmaceutical composition useful for inhibiting HIV reverse transcription, comprising an effective amount of a compound of Formula II,



and a pharmaceutically acceptable carrier, wherein

X is halo;

X¹ is trihalomethyl; pentahaloethyl; C₂₋₅ alkyl;

C₂₋₅ alkynyl;

C₃₋₅ cycloalkyl; or aryl;

Z is O or S;

R is

- (a) C₁₋₈ alkyl, unsubstituted or substituted with A, and A is halo, C₃₋₆ cycloalkyl, CN, hydroxy, C₁₋₄ alkoxy, C₂₋₄ alkynyl-C₁₋₄ alkoxy, aryloxy, C₁₋₄ alkylcarbonyl, nitro, di(C₁₋₂ alkyl)amino, C₁₋₄ alkylamino-C₁₋₂ alkyl, heterocycle, or arylthio;

SUBSTITUTE SHEET


- 4 -

- (b) C₂₋₄ alkenyl, unsubstituted or substituted with
(i) A, or
(ii) aryl, unsubstituted or substituted with A;
(c) C₂₋₅ alkynyl, unsubstituted or substituted with
(i) A, or
(ii) aryl, unsubstituted or substituted with A; or
(d) C₃₋₄ cycloalkyl, unsubstituted or substituted with
(i) A, or
(ii) aryl, unsubstituted or substituted with A;

or pharmaceutically acceptable salt thereof.

Preferred compounds include Compounds 37.2, 4, 2, 5 and 24 of Table I below, in order of descending degree of preference. These compounds have the following structure:


Compound 37.2:



(-) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one, the most preferred;


- 5 -

Compound 4:




(-) 6-chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one;

Compound 2:



(+/-) 6-chloro-4-(2-cyanophenyl)ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one;

Compound 5:




SUBSTITUTE SHEET

- 6 -

(+/-) 4-(1-chloro-1,1-difluoromethyl)-4-(2-phenyl-ethynyl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one;

Compound 24:




(+/-) 4-(2-[dimethylaminomethyl]ethynyl)-4-trifluoromethyl-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one;

or a pharmaceutically acceptable salt thereof.





The compounds of the present invention are specifically illustrated in Tables I and II below:

TABLE I



- 7 -

TABLE I (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
1		-CF ₃	186- 187.5	58nM	4100nM	
2		-CF ₃	245- 246	25	480	6nM
3(+)		-CF ₃	178- 179	2900	37,000	>200
4(-)		-CF ₃	"	8.6	69	12

*measured in nM or nanomoles/liter.

- 8 -

5

10





15

20

25

30





TABLE I (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
5		-CF ₂ Cl	154- 155	12nM	350nM	
6		-CF ₃	225- 226	1,700	19,000	
7		-CF ₃	160- 161	91	3,460	
8		-CF ₃	183- 184	163	8,470	

SUBSTITUTE SHEET

- 9 -






TABLE I (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	ClC ₉₅
9		-CF ₃	168- 171	83nM	210nM	
10		-CF ₃	159- 160	18	390	
11		-CF ₃	185- 186	16	270	6.0nM
12 (+/-)		-CF ₃	137- 147	12	280	25

SUBSTITUTE SHEET

- 10 -

TABLE I (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
13		-CF ₃	157	390nM	10 ⁵ nM	
14		-CF ₃	174- 176	130	65,000	
15		-CF ₃	165- 166	29	>10 ⁵	
16		-CF ₃	230- 240	1900	1900	78,000
17		-CF ₃	132- 133	2300	>10 ⁵	

SUBSTITUTE SHEET

TABLE I (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
18		-CF ₃	148-149	15nM	2,650nM	50nM
19		-CF ₃	136-137	24	25,000	
20		-CF ₃	162-164	145	10 ⁵	
21		-CF ₃	145-146	860	125,000	
22		"	150-151	55	3,650	

TABLE I (Cont'd)






Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
23		-CF ₃	131-133	1300nM	30,000nM	
24		-CF ₃	146.5-147.5	43	1950	100
25		-CF ₃	122-124	220	>10 ⁵	
26		-CF ₃	224-225	0.24	>10 ⁵	
27		"	203-204	550	>10 ⁵	

TABLE I (Cont'd)





















Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
28			118-120	307nM	114,250nM	1500nM
29			166-168	1,900	>10 ⁵	
30			100-101.5	410	3000	
31			140.5-141.5	410	4250	
32			172-173	5400		

TABLE I (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
33			277-278	300nM		
34			125-126	16,500	>300,000nM	
35			184-185	650	>300,000	
36			151-152	52	>300,000	
37			186-187	5,300	>10 ⁵	

- 15 -

5

10



15

20

25

30

TABLE I (Cont'd)



<u>Compound</u>	<u>R</u>	<u>X¹</u>	<u>MP(°C)</u>	<u>IC₅₀ wt</u>	<u>IC₅₀ dm</u>	<u>CIC₉₅</u>
37.2 (-)				2nM	85+nM	

+ other data on Compound 38 is provided in the Examples section.

SUBSTITUTE SHEET

- 15 -

TABLE I (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
37.2 (-)				2nM	85 ⁺ nM	

* other data on Compound 38 is provided in the Examples section.

SUBSTITUTE SHEET

5

10

15

20

25

30













TABLE I (Cont'd)

<u>Compound</u>	<u>R</u>	<u>X¹</u>	<u>MP(°C)</u>	<u>IC₅₀ wt</u>	<u>IC₅₀ dm</u>	<u>CIC₉₅</u>
37.2 (-)				2nM	85+nM	

+ other data on Compound 38 is provided in the Examples section.







- 17 -

TABLE II (Cont'd)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	ClC ₉₅
38			177-179	136nM	>300,000nM	
39			135-136	510	>300,000nM	
40			125-126	48	29,000	
41				1400nM	>300,000nM	
42			218-220	1450		
43			187-188	610		

SUBSTITUTE SHEET

TABLE II (CONT'D)

Compound	R	X ¹	MP(°C)	IC ₅₀ wt	IC ₅₀ dm	CIC ₉₅
44			206-207	15nM	>300,000nM	100nM
45			147-148	560	>300,000nM	
46			186-187	41	>300,000nM	

- 19 -

The compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as racemates, racemic mixtures or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention. The term (+/-) is intended to encompass (+) optical isomers or (-) optical isomers or mixtures thereof.

When any variable (e.g., R) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "alkenyl" is intended to cover both branched- and straight chain alkyl groups with at least one carbon-carbon double bond; "alkynyl" is intended to cover both branched- and straight chain alkyl groups with at least one carbon-carbon triple bond. "Halogen" or "halo" as used herein, means fluoro, chloro, bromo and iodo.

As used herein, with exceptions as noted, "aryl" is intended to mean phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenanthryl, anthryl or acenaphthyl.

The term heterocycle or heterocyclic, as used herein except where noted, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated, partially unsaturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl,

SUBSTITUTE SHEET

- 20 -

pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl,
imidazolyl, imidazoliny, imidazolidinyl, pyridyl, pyrazinyl,
pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl,
isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl,
5 quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl,
benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl,
benzoxazolyl, furyl, tetrahydrofuryl, benzofuranyl, tetrahydropyranyl,
thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide,
thiamorpholinyl sulfone, and oxadiazolyl.

10 The compounds of the present invention can be synthesized
by the following methods.


15

20

25

30

- 21 -

SCHEME I

SUBSTITUTE SHEET

- 22 -


In the synthesis of the benzoxazines of the present invention, the general method typically involves cyclization on a benzene nucleus as a final step. See Scheme I. The amino group of parachloroaniline is first protected with, e.g. pivaloyl chloride, to give 2. Other less preferable amino protecting groups include t-butoxy-carbonyl, acetate or isovaleroyl groups. About 2 equivalents of an alkyl lithium are then reacted with 2, preferably n-butyl lithium. No other organo metallic compounds are suitable for this metalation step. Subsequently, reaction with CF_3COOEt followed by quenching gives 3.

The synthesis of the tertiary carbinol 4 follows, by Grignard addition at the ketone of 3. The Grignard reagent must be a salt of a divalent cation, e.g. Mg^{++} or Zn^{++} . Monovalent cations are found unsuitable, such as Li^+ or Na^+ . Suitable solvents include but are not limited to THF or ether. A wide range of temperature conditions are allowed between about 0°C and about room temperature.

Ring closure to produce the compounds of the present invention 5 is accomplished with condensing agents such as 1,1'-carbonyldiimidazole, phosgene, dimethylcarbonate, diphenylcarbonate, or di-(paranitrophenyl)carbonate. Cyclization can be accomplished with any of these compounds, as well as a wide variety of others.

A specific instance of Scheme I is provided in Scheme IA. It charts the synthesis of L-741,211, which is a racemate of Compound 37.2, as further provided in Example 6.

SCHEME IA

**SUBSTITUTE SHEET**

- 23 -



1. 2 n-BuLi/THF

-78°C→0°C/1h


2. EtOCCF₃/0°C

3. 3N HCl reflux

(60%)


A1. EtMgBr/THF
50°C/1h2. A/1.5h/RT

(73-74%)



1,1'-CDI/THF


(99%)



(L-741,211)


SUBSTITUTE SHEET

- 24 -

SCHEME II

- 25 -

Scheme III illustrates substitution of a 4-acetylene group with an N-containing heterocycle. The Mannich reaction involves a condensation reaction of formaldehyde with the heterocycle, e.g. pyrrolidine. Substitution on the terminal carbon follows in the presence of CuI as catalyst.

SCHEME IV

30 Scheme IV illustrates the resolution of optical isomers of the compounds of Formula I or Formula II. In this example, (-) camphoric acid is the resolving agent. A wide variety of other resolving agents are suitable, including *O*-methyl mandelic acid chloride or Mosher's reagent. It is apparent to the skilled artisan how to separate such isomers.

SUBSTITUTE SHEET


- 26 -

Scheme IVA is specifically adapted to the resolution of L-741,211 in the isolation of L-743,726. See Scheme IVA, and Example 6.

5

SCHEME IVA

10




(L-741,211)

15

 $(-)$ -Camphanyl chloride4-DMAP/ Et_3N / CHCl_3

20



25

Crystallization from
Hexane

(90% recovery)

30

SUBSTITUTE SHEET

- 27 -

5



10

15

20

25


30



L-743,726

Compound 37.2

- 28 -

SCHEME V

10 Cyclopropyl acetylene is prepared by Scheme V in accordance with published procedures, e.g. C. E. Hudson et al., J. Am. Chem. Soc. 94, 1158 (1972) and W. Schoberth et al., Synthesis, 703 (1972).

15 The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful
20 antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV reverse transcriptase, e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these purposes.

25 The compounds of the present inventions are useful in the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not
30 limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by e.g., blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.

The particular advantage of the compounds of this invention is their potent inhibition against HIV reverse transcriptase rendered resistant to other antivirals, such as L-697,661, which is 3-([(4,7-dichloro-1,3-benzoxazol-2-yl)methyl]-amino)-5-ethyl-6-methyl-

- 29 -

pyridin-2(1H)-one; or L-696,229, which is 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2(1H)-one; or AZT.

For these purposes, the compounds of the present invention may be administered orally, parenterally (including subcutaneous
5 injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.

Thus, in accordance with the present invention there is
10 further provided a method of treating and a pharmaceutical composition for treating HIV infection and AIDS. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically-effective amount of a compound of the present invention.

15 These pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories.

When administered orally as a suspension, these
20 compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art. As immediate release
25 tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.

When administered by nasal aerosol or inhalation, these
30 compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

- 30 -

The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable
5 dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.

When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable
10 non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.

The compounds of this invention can be administered orally to humans in a dosage range of 1 to 100 mg/kg body weight in divided
15 doses. One preferred dosage range is 0.1 to 10 mg/kg body weight orally in divided doses. Another preferred dosage range is 0.1 to 20 mg/kg body weight orally in divided doses. For combination therapy with nucleoside analogs, a preferred dosage range is 0.1 to 20 mg/kg
20 body weight for the compounds of this invention administered orally in divided doses, and 50 mg to 5 g/kg body weight for nucleoside analogs administered orally in divided doses. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors
25 including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

The present invention is also directed to combinations of
30 the HIV reverse transcriptase inhibitor compounds with one or more agents useful in the treatment of AIDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective

- 31 -

amounts of the AIDS antivirals, immunomodulators, antiinfectives, or vaccines, such as those in the following Table.

TABLE

5

ANTIVIRALS

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
AL-721	Ethigen (Los Angeles, CA)	ARC, PGL HIV positive, AIDS
Recombinant Human Interferon Beta	Triton Biosciences (Alameda, CA)	AIDS, Kaposi's sarcoma, ARC
Acemannan	Carrington Labs (Irving, TX)	ARC (See also immunomodulators)
Cytovene	Syntex	sight threatening CMV
Ganciclovir	(Palo Alto, CA)	peripheral CMV retinitis
d4T Didehydrodeoxy- thymidine	Bristol-Myers (New York, NY)	AIDS, ARC
ddI Dideoxyinosine	Bristol-Myers (New York, NY)	AIDS, ARC
EL10	Elan Corp, PLC (Gainesville, GA)	HIV infection (See also immunomodulators)

10

15

20

25

30

- 32 -

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
5	Trisodium Phosphonoformate	Astra Pharm. Products, Inc. (Westborough, MA)	CMV retinitis, HIV infection, other CMV infections
	Dideoxycytidine; ddC	Hoffman-La Roche (Nutley, NJ)	AIDS, ARC
10	Novapren	Novaferon Labs, Inc. (Akron, OH) Diapren, Inc. (Roseville, MN, marketer)	HIV inhibitor
15	Peptide T Octapeptide Sequence	Peninsula Labs (Belmont, CA)	AIDS
20	Zidovudine; AZT	Burroughs Wellcome (Rsch. Triangle Park, NC)	AIDS, adv, ARC pediatric AIDS, Kaposi's sarcoma, asymptomatic HIV infection, less severe HIV disease, neurological involvement, in combination with therapies.
25			
30			

SUBSTITUTE SHEET

- 33 -

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
5	Ansamycin LM 427	Adria Laboratories (Dublin, OH) Erbamont (Stamford, CT)	ARC
10	Dextran Sulfate	Ueno Fine Chem. Ind. Ltd. (Osaka, Japan)	AIDS, ARC, HIV positive asymptomatic
	Virazole Ribavirin	Viratek/ICN (Costa Mesa, CA)	asymptomatic HIV positive, LAS, ARC
15	Alpha Interferon	Burroughs Wellcome (Rsch. Triangle Park, NC)	Kaposi's sarcoma, HIV in combination w/Retrovir
20	Acyclovir	Burroughs Wellcome	AIDS, ARC, asymptomatic HIV positive, in combination with AZT.
25	Antibody which neutralizes pH labile alpha aberrant Interferon in an immuno-adsorption column	Advanced Biotherapy Concepts Rockville, MD)	AIDS, ARC
30			

SUBSTITUTE SHEET

- 34 -

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
5	L-697,661	Merck (Rahway, NJ)	AIDS, ARC, asymptomatic HIV positive, also in combination with AZT.
10	L-696,229	Merck (Rahway, NJ)	AIDS, ARC, asymptomatic HIV positive, also in combination with AZT.
15	L-735,524	Merck (Rahway, NJ)	AIDS, ARC, asymptomatic HIV positive, also in combination with AZT.

IMMUNO-MODULATORS

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
20	AS-101	Wyeth-Ayerst Labs. (Philadelphia, PA)	AIDS
25	Bropirimine	Upjohn (Kalamazoo, MI)	advanced AIDS
30	Acemannan	Carrington Labs, Inc. (Irving, TX)	AIDS, ARC (See also antivirals)

SUBSTITUTE SHEET

- 35 -

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
	CL246,738	American Cyanamid (Pearl River, NY) Lederle Labs (Wayne, NJ)	AIDS, Kaposi's sarcoma
5			
	EL10	Elan Corp, PLC (Gainesville, GA)	HIV infection (See also antivirals)
10			
	Gamma Interferon	Genentech (S. San Francisco, CA)	ARC, in combination w/TNF (tumor necrosis factor)
15			
	Granulocyte Macrophage Colony Stimulating Factor	Genetics Institute (Cambridge, MA) Sandoz (East Hanover, NJ)	AIDS
20			
	Granulocyte Macrophage Colony Stimulating Factor	Hoeschst-Roussel (Somerville, NJ) Immunex (Seattle, WA)	AIDS
25			
	Granulocyte Macrophage Colony Stimulating Factor	Schering-Plough (Madison, NJ)	AIDS AIDS, in combination w/AZT
30			
	HIV Core Particle Immunostimulant	Rorer (Ft. Washington, PA)	seropositive HIV

SUBSTITUTE SHEET

- 36 -

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
5	IL-2 Interleukin-2	Hoffman-La Roche (Nutley, NJ) Immunex	AIDS, ARC, HIV, in combination w/AZT
	Immune Globulin Intravenous (human)	Cutter Biological (Berkeley, CA)	pediatric AIDS, in combination w/AZT
10	IMREG-1	Imreg New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL
15	IMREG-2	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL
	Imuthiol Diethyl Dithio Carbamate	Merieux Institute (Miami, FL)	AIDS, ARC
20	Alpha-2 Interferon	Schering Plough (Madison, NJ)	Kaposi's sarcoma w/AZT: AIDS
25	Methionine- Enkephalin	TNI Pharmaceutical (Chicago, IL)	AIDS, ARC
	MTP-PE Muramyl-Tripeptide	Ciba-Geigy Corp. (Summit, NJ)	Kaposi's sarcoma
30	Granulocyte Colony Stimulating Factor	Amgen (Thousand Oaks, CA)	AIDS, in combination w/AZT

SUBSTITUTE SHEET

- 37 -

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
5	rCD4 Recombinant Soluble Human CD4	Genentech (S. San Francisco, CA)	AIDS, ARC
	Rocombinant Soluble Human CD4	Biogen (Cambridge, MA)	AIDS, ARC
10	Interferon Alfa 2a	Hoffman-La Roche (Nutley, NJ)	Kaposi's sarcoma AIDS, ARC, in combination w/AZT
15	SK&F106528 Soluble T4	Smith, Kline & French Laboratories (Philadelphia, PA)	HIV infection
20	Thymopentin	Immunobiology Research Institute (Annandale, NJ)	HIV infection
25	Tumor Necrosis Factor; TNF	Genentech (S. San Francisco, CA)	ARC, in combination w/gamma Interferon

ANTI-INFECTIVES

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
30	Clindamycin with Primaquine Fluconazole	Upjohn (Kalamazoo, MI) Pfizer (New York, NY)	PCP cryptococcal meningitis, candidiasis

SUBSTITUTE SHEET

- 38 -

	Pastille Nystatin Pastille	Squibb Corp (Princeton, NJ)	prevention of oral candidiasis
5	Ornidyl Eflornithine	Merrell Dow (Cincinnati, OH)	PCP
	Pentamidine Isethionate (IM & IV)	LyphoMed (Rosemont, IL)	PCP treatment
10	Piritrexim	Burroughs Wellcome (Rsch. Triangle Park, NC)	PCP treatment
15	Pentamidine isethionate for inhalation	Fisons Corporation (Bedford, MA)	PCP prophylaxis
20	Spiramycin	Rhone-Poulenc Pharmaceuticals (Princeton, NJ)	cryptosporidial diarrhea
25	Intraconazole- R51211	Janssen Pharm. (Piscataway, NJ)	histoplasmosis; cryptococcal meningitis
	Trimetrexate	Warner-Lambert	PCP

OTHER

30	<u>Drug Name</u> Recombinant Human Erythropoietin	<u>Manufacturer</u> Ortho Pharm. Corp. (Raritan, NJ)	<u>Indication</u> severe anemia assoc. with AZT therapy
----	---	--	---

SUBSTITUTE SHEET

- 39 -

	<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
	Megestrol Acetate	Bristol-Myers (New York, NY)	treatment of anorexia assoc.w/AIDS
5	Total Enteral Nutrition	Norwich Eaton Pharmaceuticals (Norwich, NY)	diarrhea and malabsorption related to AIDS

10 It will be understood that the scope of combinations of the
compounds of this invention with AIDS antivirals, immunomodulators,
anti-infectives or vaccines is not limited to the list in the above Table,
but includes in principle any combination with any pharmaceutical
composition useful for the treatment of AIDS. For example, a
15 compound of Formula I or Formula II may be suitably administered in
combination with a nucleoside analog having known biological activity
against HIV reverse transcriptase. Appropriate nucleoside analogs are
generally chain terminators and include AZT, ddC, ddI, D4T, HEPT
and 3'-fluoro-2',3'-dideoxythymidine.

20 AZT is synthesized by the methods of J.P. Horwitz et al., J.
Org. Chem. 29, 2076 (1964); R.P. Glinski et al., J. Org. Chem. 38,
4299 (1973); C.K. Chu et al., Tetrahedron Letters 29, 5349 (1988).
Application of AZT as a therapeutic drug in the treatment of AIDS is
disclosed in U.S. 4,724,232.

25 The compound ddC is synthesized by the methods of J.P.
Horwitz et al., J. Org. Chem. 32, 817 (1967); R. Marumoto, Chem.
Pharm. Bull. 22, 128 (1974); and T.-S. Lin et al., J. Med. Chem. 30,
440 (1987).

30 D4T is synthesized by the methods of Herdewijn, P. et al.,
J. Med. Chem. 30, 1270 (1987).

HEPT is synthesized by the methods of Miyasaka, T. et. al.
J. Med. Chem. 32, 2507 (1989); and A. Rosowsky, J. Med. Chem. 24,
1177 (1981). The synthesis of ddC, ddI and AZT are also described in
EPO 484071.

SUBSTITUTE SHEET

- 40 -

The compound 3'-fluoro-2',3'-dideoxythymidine is synthesized by the procedures of Herdewijn, P. et al., J. Med. Chem. 30, 1270 (1987). The compound L-735,524 is N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide, or
5 pharmaceutically acceptable salt thereof. L-697,661 or '661' is 3-([4,7-dichloro-1,3-benzoxazol-2-yl)methyl]-amino)-5-ethyl-ethyl-6-methylpyridin-2(1H)-one; L-696,229 is 3-[2-(1,3-benzoxazol-2-yl)-ethyl]-5-ethyl-6-methyl-pyridin-2(1H)-one. The synthesis of L-697,661 and L-
10 696,229 is described in EPO 484071, and EPO 462800, both herein incorporated by reference.

Preferred combinations are simultaneous, intermittent, or alternating treatments of L-743,726 with or without an inhibitor of HIV protease. An optional third component in the combination is a
15 nucleoside inhibitor of HIV reverse transcriptase, such as AZT, ddC or ddI. A preferred inhibitor of HIV protease is L-735,524. Other preferred inhibitors of HIV reverse transcriptase include L-697,661. These combinations may have synergistic effects on limiting the spread of HIV. Preferred combinations include the following: (1) L-743,726
20 with L-735,524, and, optionally any of L-697,661, AZT, ddI or ddC; (2) L-743,726 and any of L-697,661, AZT, ddI or ddC. Pharmaceutically acceptable salts of these combinations are also included.

25

EXAMPLE 1

(+/-) 4-(1,1,1,-trifluoromethyl)-4-(1-buten-4-yl)-6-chloro-1,4-dihydro-
2H-3,1-benzoxazin-2-one; (Compound 15)

30

Step A: N-(4-chlorophenyl)-2,2-dimethylpropanamide

To a 5L 3 necked round bottomed flask with an overhead stirrer was added 4-chloroaniline (127.57 g, 1 mole), 1200 mL of CHCl₃, and 1200 mL of saturated aqueous Na₂CO₃ solution. An addition funnel was attached to the flask and charged with 2,2-

- 41 -

dimethylpropanoyl chloride (129 mL, 1.05 mole). The acid chloride was added dropwise to the vigorously stirred mixture over 1h. The resulting mixture was stirred at ambient temperature for an additional 23h. Some of the product separated from the mixture as white crystals. These crystals were collected by filtration. The filtrate was transferred to a separatory funnel and the layers were separated. The chloroform layer was washed with water and brine. Drying (MgSO_4), filtration, and removal of the solvent in vacuo gave additional product. The two portions of product were combined and recrystallized from boiling EtOAc-hexanes to give 185.6 g of N-(4-chlorophenyl)-2,2-dimethylpropanamide as a white crystalline solid.

Step B: 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone

To an oven dried, 3L, 3 necked round bottomed flask with an overhead stirrer, argon inlet, and a 500 mL oven dried addition funnel was added N-(4-chlorophenyl)-2,2-dimethylpropanamide (100 g, 472 mmol) and dry THF (1L). This solution was cooled in an ice bath to 0°C and the addition funnel was charged with n-butyllithium (387 mL of a 2.5 M solution in hexanes, 968 mmol). The n-butyllithium solution was added dropwise to the amide solution slowly over 1h, maintaining the temperature below +5°C. The resulting solution was aged at 0°C for 1h during which time an orange precipitate formed. To this mixture was added ethyl 1,1,1-trifluoroacetate (115 mL, 968 mmol), dropwise over 1h. The resulting clear solution was aged an additional 30 min. The reaction was quenched with 5% aqueous HCl. The mixture was diluted with 1L of EtOAc and the layers were separated. The organic phase was washed with brine, dried (MgSO_4), filtered and concentrated in vacuo, to give 160 g of a yellow oil. This material was suspended in 1L of 3N aqueous HCl and the solution was heated at reflux for 24h. The cooled solution was diluted with 1L of EtOAc and the mixture was made basic with concentrated NH_4OH . The layers were separated and the organic phase was washed with brine, dried (MgSO_4), filtered, concentrated in vacuo, and chromatographed on 1.5 kg of silica gel using 15% EtOAc in hexane as eluant. The chromatographed material

SUBSTITUTE SHEET

- 42 -

was recrystallized from boiling hexane to give 57 g (54%) of pure 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone as bright yellow crystals, mp: 91-92°C. ¹H NMR (CDCl₃): δ 6.46 (br s, 2H), 6.69 (d, 1H, J=9.2 Hz), 7.32 (dd, 1H, J=2.4, 9.2 Hz), 7.70 (d, 1H, J=2.4 Hz).

Step C: (+/-) 2-(2-Amino-5-chlorophenyl)-1,1,1-trifluoro-5-hexen-2-ol

To a 300 mL oven dried 3 necked, round bottomed flask with a stirring bar, argon inlet, addition funnel and a reflux condenser was added magnesium (turnings, 3.03 g, 125 mmol) and dry THF (75 mL). To this well stirred mixture was added 4-bromo-1-butene (12.0 mL, 118.21 mmol) at such a rate as to maintain a gentle reflux. When the addition was complete, the mixture was aged 30 min then cooled to 0°C in an ice bath. To this well stirred solution was added a solution of 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone (5.00 g, 22.36 mmol) in THF (35 mL), dropwise over 30 min. The cooling bath was allowed to expire and the mixture was stirred 20 h at ambient temperature. The reaction was diluted with EtOAc and 10% aqueous citric acid. This mixture was stirred for 4 h. The layers were separated and the organic phase was washed with aqueous NaHCO₃ and brine. Drying (MgSO₄), filtration, removal of the solvent *in vacuo*, and chromatography on 300g of silica gel using 15% EtOAc in hexane as eluant gave 4.80 g of (+/-) 2-(2-amino-5-chlorophenyl)-1,1,1-trifluoro-5-hexen-2-ol as a yellow solid.

Step D: (+/-) 4-(1,1,1,-trifluoromethyl)-4-(1-buten-4-yl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one

To a 200 mL round bottomed flask with a stirring bar, argon inlet and a reflux condenser was added (+/-) 2-(2-Amino-5-chlorophenyl)-1,1,1-trifluoro-5-hexen-2-ol (4.80 g, 17.16 mmol), 1,1'-carbonyldiimidazole (13.91 g, 85.81 mmol) and dry THF (75 mL). This mixture was heated at 60°C for 18h. The cooled reaction mixture was diluted with EtOAc and washed with H₂O (3X 200 mL) and brine (250 mL). Drying (MgSO₄), filtration, removal of the solvent *in*

- 43 -

vacuo, followed by recrystallization from boiling EtOAc-hexane gave 3.22g of (+/-) 4-(1,1,1-trifluoromethyl)-4(1-buten-4-yl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one as a white crystalline solid, mp: 165-166°C. ¹H NMR (CDCl₃): δ 1.99 (m, 1H), 2.09-2.40 (m, 3H), 5.00 (d, 1H, J=1.4 Hz), 5.03 (dd, 1H, J=1.4, 7.9), 5.78 (m, 1H), 6.85 (d, 1H, J=8.6 Hz), 7.21 (br s, 1H), 7.35 (dd, 1H, J=2.2, 8.6 Hz), 9.63 (br s, 1H).

EXAMPLE 2

(+/-) 6-Chloro-4-ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one (Compound 26)

Step A: 2-(2-amino-5-chlorophenyl)-1,1,1-trifluoro-3-butyn-2-ol

A 500 ml 3-neck round bottom flask fitted with an addition funnel, argon inlet, stirring bar and digital thermometer was charged with ethynyl magnesium bromide (0.5M in hexane; 268 mL, 134 mmol) then chilled to -78°C. Dropwise addition of a solution of 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone (6.0 g, 26.8 mmol) in 50 mL THF was completed after 15 minutes keeping the temperature ≤ -55°C. The reaction mixture was stirred for 16 h after slowly warming to room temperature. The dark red solution was quenched at -5°C by dropwise addition of saturated aqueous ammonium chloride solution (60 mL). Ethyl acetate extraction followed by washes of 10% citric acid, saturated sodium bicarbonate, water and brine afforded 8.5 g crude product after drying over sodium sulfate, filtration, and evaporation of solvent. Purification via flash chromatography using 15-20% ethyl acetate : hexane afforded pure 2-(2-amino-5-chlorophenyl)-1,1,1-trifluoro-3-butyn-2-ol (5 g light brown oil, 75% yield).

Step B: (+/-) 6-Chloro-4-ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one

A THF solution of 2-(2-amino-5-chlorophenyl)-1,1,1-trifluoro-3-butyn-2-ol (5.0 g, 20.0 mmol in 225 mL THF) was treated with 1,1'-carbonyldiimidazole (13.0 g, 80.0 mmol) and heated in an oil

- 44 -

bath at 60°C for 17 h. The THF was removed in vacuo, the residue dissolved in ethyl acetate then washed with 10% citric acid, sodium bicarbonate, water and brine before drying over sodium sulfate. Following filtration and evaporation in vacuo the crude product was isolated (3.6 g) and recrystallized from ethyl acetate : hexane. The product (+/-) 6-chloro-4-ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one was isolated as a white crystalline solid (3.22 g, 58.4% yield): mp 226-227°C. ¹H-NMR (CDCl₃ + trace DMSO): δ 3.16 (s, 1H), 6.98 (d, J=3.3 Hz, 1H), 7.35 (m, 1H), 7.51 (s, 1H), 10.66 (s, 1H).

EXAMPLE 3

(+/-) 6-Chloro-4-(1,1,1-trifluoromethyl)-4-[(3-(1-pyrrolidinyl))-1-propynyl]-1,4-dihydro-2H-3,1-benzoxazin-2-one (Compound 7)

A dioxane solution of (+/-) 6-chloro-4-ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one (150 mg, 0.544 mmol), pyrrolidine (52.2 µL, 0.626 mmol), paraformaldehyde (20.5 mg, 0.681 mmol), acetic acid (31.1 µL, 0.544 mmol) and copper (I) chloride (20.5 mg, 0.207 mmol in 3.5 ml dioxane) was heated to 50°C in an oil bath for approximately 2 h. The reaction mixture was quenched into 2N HCl and extracted with ethyl acetate. The aqueous layer was neutralized with solid potassium carbonate and extracted with ethyl acetate (3x). The combined extracts were washed with water and brine before drying over sodium sulfate to afford 140 mg crude product. Chromatographic purification on silica gel and recrystallization from ethyl acetate : hexane afforded crystalline (+/-) 6-chloro-4-(1,1,1-trifluoromethyl)-4-[(3-(1-pyrrolidinyl))-1-propynyl]-1,4-dihydro-2H-3,1-benzoxazin-2-one (89 mg, 46% yield): MP 160-161°C (dec). ¹H-NMR (CDCl₃): δ 1.85-1.89 (m, 4H), 2.68-2.71 (m, 4H), 3.67 (s, 1H), 6.88 (d, J= 8.55 Hz, 1H), 7.40 (dd, J= 2.19, 8.54 Hz, 1H), 7.55 (s, 1H), 9.45 (s, 1H).

- 45 -

(+/-) 6-Chloro-4-(2-cyanophenyl)ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one (Compound 2)

A solution of 6-Chloro-4-ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one (138 mg, 0.5 mmol) in 3 mL of dry THF was stirred at -78°C. To this solution was added 0.4 mL (1.0 mmol) of n-butyllithium, 2.5 M in hexane. The anion was aged for 10 minutes at -78°C then 1 mL of ZnCl₂ (1 M in ether) solution was added. The reaction mixture was allowed to stir at -78°C for 15 minutes, the ice bath was removed and the mixture slowly warmed to 0°C over 30 min. To the reaction mixture was added a solution of 2-iodobenzonitrile (149 mg, 0.65 mmol) in 2 mL THF, followed by tetrakis(triphenylphosphine)palladium(0) (56 mg, 0.05 mmol). The reaction was allowed to warm to r.t. and continued to stir over 15 hours. The reaction mixture was quenched with 10 mL of 2N HCl, extracted with 2x200 mL EtOAc and the combined extracts were washed with H₂O, brine and dried over MgSO₄. The solvent was removed to give 195 mg of an oil which was flashed chromatographed on silica gel (20% EtOAc in hexane) to afford 60 mg of the unreacted starting material and 35 mg of the coupled product. The latter was triturated with ether to yield 25 mg of (+/-) 6-Chloro-4-(2-cyanophenyl)ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one. mp: 245-246°C FAB. MS M+1=377 m/e. ¹H NMR (CDCl₃): δ 6.82-6.85 (d, J=8.5 Hz, 1H); 7.40-7.44 (dd, J=2.1, 8.5 Hz, 1H); 7.56-7.79 (m, 5H); 8.00 (s, 1H).

EXAMPLE 4

(+/-) 4-(1-Chloro-1,1-difluoromethyl)-4-(2-phenylethynyl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one (Compound 5)

Step A: 1-(2-amino-5-chlorophenyl)-2-chloro-2,2-difluoroethanone

To an oven dried, 300 mL, 3 necked round bottomed flask with a magnetic stirring bar, argon inlet, and a 100 mL oven dried addition funnel was added N-(4-chlorophenyl)-2,2-dimethyl-

- 46 -

propanamide (10 g, 47.2 mmol) and dry THF (100 mL). This solution was cooled in an ice bath to 0°C and the addition funnel was charged with n-butyllithium (38.7 mL of a 2.5 M solution in hexanes, 96.8 mmol). The n-butyllithium solution was added dropwise to the amide solution slowly over 1h, maintaining the temperature below +5°C. The resulting solution was aged at 0°C for 1h during which time an orange precipitate formed. To this mixture was added ethyl 1-chloro-1,1-difluoroacetate (10.2 mL, 96.8 mmol), dropwise over 15 min. The resulting clear solution was aged an additional 30 min. The reaction was quenched with 5% aqueous HCl. The mixture was diluted with 1L of EtOAc and the layers were separated. The organic phase was washed with brine, dried (MgSO₄), filtered and concentrated in vacuo, to give 160 g of a yellow oil. This material was suspended in 200 mL of 3N aqueous HCl and the solution was heated at reflux for 24h. The cooled solution was diluted with 500 mL of EtOAc and the mixture was made basic with concentrated NH₄OH. The layers were separated and the organic phase was washed with brine, dried (MgSO₄), filtered, concentrated in vacuo, and chromatographed on 350 g of silica gel using 15% EtOAc in hexane as eluant. The chromatographed material was recrystallized from boiling hexane to give 5.5 g of pure 1-(2-amino-5-chlorophenyl)-2-chloro-2,2-difluoroethanone as bright yellow crystals, mp: 55-56°C. ¹H NMR (CDCl₃): δ 6.43 (br s, 2H), 6.69 (d, 1H, J=9.0 Hz), 7.31 (dd, 1H, J=2.4, 9.0 Hz), 7.80 (d, 1H, J=2.4 Hz).

Step B: (+/-) 2-(2-amino-5-chlorophenyl)-4-phenyl-1-chloro-1,1-difluoro-3-butyne-2-ol

To a 100 mL, 3 necked, oven dried round bottomed flask, with a stirring bar, argon inlet, reflux condenser, and a septum was added ethynyl benzene (2.13 g, 20.83 mmol), dry THF (50 mL) and ethyl magnesium bromide (6.94 mL of a 3.0M solution in ether). This mixture was aged 2h at ambient temperature then a solution of 1-(2-amino-5-chlorophenyl)-2-chloro-2,2-difluoroethanone (1.00 g, 4.17 mmol) in THF (6 mL) was added with a syringe. The resulting orange-red solution was stirred at ambient temperature for 21.5h. The reaction

- 47 -

was quenched by addition of 1N HCl (50 mL) then diluted with EtOAc. The solution was then made basic with concentrated NH₄OH and the layers were separated. The organic phase was washed with water and brine. Drying (MgSO₄), filtration, removal of the solvent in vacuo,
5 and chromatography on silica gel using 20% EtOAc in hexane as eluant gave 1.02 g of (+/-) 2-(2-amino-5-chlorophenyl)-4-phenyl-1-chloro-1,1-difluoro-3-butyne-2-ol as an off white solid. ¹H NMR (CDCl₃): δ 4.42 (br s, 2H), 5.10 (br s, 1H), 6.65 (d, 1H, J=8.5 Hz), 7.15 (dd, 1H, J=2.4, 8.5 Hz), 7.38 (m, 3H), 7.55 (m, 2H), 7.70 (d, J=2.4 Hz).
10

Step C: (+/-) 4-(1-Chloro-1,1-difluoromethyl)-4-(2-phenylethynyl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one

To a 100 mL round bottomed flask with a stirring bar, reflux condenser, and an argon inlet was added (+/-) 2-(2-amino-5-chlorophenyl)-4-phenyl-1-chloro-1,1-difluoro-3-butyne-2-ol (0.81 g, 2.37 mmol), dry THF (25 mL), and 1,1'-carbonyldiimidazole (1.919 g, 11.84 mmol). This solution was heated at 60°C for 20h. The cooled reaction mixture was diluted with EtOAc and washed with 0.5N HCl, H₂O, and brine. Drying (MgSO₄), filtration, and removal of the
15 solvent in vacuo gave 890 mg of an oil. This material was chromatographed on 80 g of silica gel using 20% EtOAc in hexane as eluant. The chromatographed material was recrystallized from boiling EtOAc-hexanes to give 507 mg, (58%) of (+/-) 4-(1-chloro-1,1-difluoromethyl)-4-(2-phenylethynyl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one as white needles, mp: 154-155°C. ¹H NMR (CDCl₃):
20 δ 6.89 (d, 1H, J=8.4 Hz), 7.35-7.48 (m, 4H), 7.56 (m, 2H), 7.64 (br s, 1H), 9.19 (br s, 1H).
25

EXAMPLE 5

(-) 6-Chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (Compound 4)
30

- 48 -

Step A: 2-(2-Amino-5-chlorophenyl)-4-phenyl-1,1,1-trifluoro-3-butyn-2-ol

A solution of lithio phenylacetylide, prepared from 4.83 mL of phenylacetylene (0.044 mol) and 17.2 mL of a 2.5 N solution of n-butyllithium in hexane (0.043 mol) in 50 mL of THF at -78°C, was treated with 11.4 g of magnesium bromide etherate (0.044 mol) over 5 minutes. The mixture was allowed to warm to -20°C and stirring under argon was continued for 30 minutes. The mixture was then cooled to -60°C and a solution containing 2.5 g (0.011 mol) of 1-(2-amino-5-chloro)-2,2,2-trifluoromethylethanone, previously complexed with an equivalent (2.8 g, 0.011 mol) of magnesium bromide etherate in 25 mL of THF, was added. The reaction mixture was allowed to stir at 15° for one hour before being cooled to 0°C and treated dropwise with a mixture of 30 mL each of saturated aqueous ammonium chloride solution and water. The mixture was extracted with 2 x 100 mL portions of ethyl ether, the combined organic phases were washed with brine and dried over MgSO₄. Removal of the drying agent and solvents left 6 g of an oil which was flash chromatographed on silica gel, eluting with 20% EtOAc in hexane, to afford 2.5 g of 2-(2-amino-5-chlorophenyl)-4-phenyl-1,1,1-trifluoro-3-butyn-2-ol. ¹H-NMR (CDCl₃): δ 4.63 (br s, 3H), 6.69 (d, J=8.5 Hz, 1H), 7.15 (d, J= 2 Hz, 1H), 7.17 (d, J=2 Hz, 1H), 7.35-7.44 (m, 3H), 7.53-7.56 (m, 2H), 7.66 (d, J=2 Hz, 1H). FAB MS M+H = 326 m/e.

Step B: (±) 6-Chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (Compound 12)

A solution of 2-(2-amino-5-chlorophenyl)-4-phenyl-1,1,1-trifluoro-3-butyn-2-ol (2.0 g, 6.1 mmol) and 11.0 g (12.0 mmol) of 1,1'-carbonyldiimidazole in 300 mL of dry THF was stirred under argon at 55°C for 24 hours. The solvent was removed on a rotary evaporator and the residue was partitioned between 200 mL of ether and 400 mL of water. The layers were separated and the aqueous extracted once more with ether. The combined ether extracts were washed with 2 x 200 mL 10% citric acid and then with brine before

- 49 -

drying over MgSO_4 . Removal of the drying agent and solvent provided 1.5 g (70%) of the crude title compound as an oil. Trituration with ether-hexane afforded 875 mg of (\pm) 6-chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as a white solid, partial melt at 137° , clear at 147°C . $^1\text{H-NMR}$ (CDCl_3): δ 6.92 (d, $J=8$ Hz, 1H), 7.30-7.49 (m, 4H), 7.58-7.65 (m, 3H), 8.99 (s, 1H).

Step C: 6-Chloro-1-(1S)-camphanoyl-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one

To a solution containing (\pm) 6-chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (2.24 g, 6.37 mmol), 4-dimethylaminopyridine (0.10 g, 0.8 mmol), and (-) camphanic acid chloride (2.07 g, 9.55 mmol) in 60 mL of dry dichloromethane, stirred under argon in an ice bath, was added triethylamine (2.22 mL, 15.9 mmol). The cooling bath was removed and the reaction was allowed to proceed at room temperature. When the reaction was complete by thin layer chromatography (SiO_2 , 4% EtOAc in CHCl_3), the solution was diluted with 200 mL of CHCl_3 and washed twice with 10% citric acid, then with brine. Upon drying (MgSO_4) the solvent was removed on a rotary evaporator and the foamy residue was subjected to flash chromatography, eluting with CHCl_3 . There was obtained 575 mg of diastereomer I of 6-chloro-(1S)-camphanoyl-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as an oil, $^1\text{H-NMR}$ (CDCl_3): δ 0.85 (s, 3H), 1.08 (s, 3H), 1.22 (s, 3H), 1.73-1.85 (m, 1H), 1.92-2.08 (m, 1H), 2.50-2.67 (m, 2H), 7.30-7.79 (m, 8H). This was followed by 1.52 g of mixed fractions (diastereomers I and II). Continued elution afforded 680 mg of the slower-moving diastereomer (II) of the title compound which, upon trituration with an ether/hexane mixture, gave clumps of white needles, mp $177-178.5^\circ\text{C}$; $^1\text{H-NMR}$ (CDCl_3): δ 0.83 (s, 3H), 1.12 (s, 3H), 1.23 (s, 3H), 1.73-1.86 (m, 1H), 1.93-2.06 (m, 1H), 2.50-2.63 (m, 2H), 7.38-7.51 (m, 4H), 7.49-7.62 (m, 2H), 7.72 (d, $J=9$ Hz, 1H), 7.76 (d, $J=2$ Hz, 1H).

SUBSTITUTE SHEET

- 50 -

The 1.52 g of isomer mixture from the flash chromatography was dissolved in 75 mL of ether, the solution diluted with 50 mL of hexane, and then seeded with a crystal of isomer II. Slow crystallization afforded an additional 385 mg of isomer II which was recrystallized from ether/hexane to give >96% diastereomerically pure material by HPLC.

Step D: (-) 6-Chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one

The crystalline diastereomer(II) of 6-chloro-1-(1S)-camphanoyl-4-phenylethynyl-4-trifluoromethyl-1,2-dihydro-4(H)-3,1-benzoxazin-2-one (53 mg, 0.10 mmol) was dissolved in 8 mL of 2-propanol at 45°C under an atmosphere of argon. To the solution was added 0.27 mL of a 10% aqueous solution of K₂CO₃. Stirring was continued for 10 min., by which time all of the starting material had been consumed (TLC, SiO₂, 4% EtOAc in CHCl₃). The solution was concentrated in vacuo and the residue taken up in ether. After washing with 0.1N HCl and brine, the ether solution was dried (MgSO₄), filtered and evaporated in vacuo to an oily solid which was purified by SiO₂ chromatography, eluant 5% 2-propanol in hexane. (-) 6-Chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one was obtained as white needles from ether/hexane, m.p. 178-179°C; [α]_D²⁰ = - 92.5° (CHCl₃, c=0.0012 g mL⁻¹); ¹H-NMR (CDCl₃): δ 6.87 (d, J=8.5 Hz, 1H), 7.37-7.50 (m, 4H), 7.56-7.63 (m, 3H), 8.60 (s, 1H).

Step E: (+) 6-Chloro-4-phenylethynyl-4-trifluoromethyl 1,4-dihydro-2H-3,1-benzoxazin-2-one (Compound 3)

(+) 6-Chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one was prepared from the non-crystalline product of Step C, diastereomer I, in a manner according to Step D: m.p. 178-179°C; [α]_D²⁰ = + 87.6° (CHCl₃, c=0.0050 g mL⁻¹); ¹H-NMR(CDCl₃): δ 6.87 (d, J=8.5 Hz, 1H), 7.37-7.50 (m, 4H), 7.56-7.63 (m, 3H), 8.60 (s, 1H).

- 51 -

EXAMPLE 6

5 (-) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L- 743,726, Compound 37.2) and (+) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L- 743,725)

10 Step A: 2-(2-Amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3-butyn-2-ol

A solution of bromomagnesium cyclopropylacetylide. was prepared from 23 g of cyclopropylacetylene (0.348 mol) in 250 mL of THF by dropwise addition of 116 mL of a 3.0 M solution of ethylmagnesium bromide in ether (0.348 mol) over 1h. This solution was maintained at 0°C for 1h, then at 40°C for 3h. To this solution, recooled to 0°C, 15.56 g of 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoromethylethanone (0.0696 mol), was added as a solid, portionwise over 5 min. The reaction mixture was allowed to stir at 0° for 1.5 hours. The reaction was quenched at 0°C by dropwise addition of 700 mL of saturated aqueous ammonium chloride solution. The mixture was extracted with 2 x 400 mL portions of ethyl acetate, the combined organic phases were washed with brine and dried over MgSO₄. Removal of the drying agent and solvents left a yellow solid. This material was recrystallized from boiling hexanes (100 mL final volume) to afford 14.67 g of 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3-butyn-2-ol. A second crop (2.1 g) was obtained from concentrating the mother liquors. mp: 153-154°C. ¹H-NMR (CDCl₃) : δ 0.84 (m, 2H), 0.90 (m, 2H), 1.38 (m, 1H), 4.50 (br s, 3H), 6.69 (d, J = 8.5 Hz, 1H), 7.13 (dd, J = 2.5, 8.5 Hz, 1H), 7.55 (d, J = 2.5 Hz, 1H).

30 Step B: (±) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-741,211)

A solution of 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluoro-3-butyn-2-ol (15.00 g, 0.0518 mol) and 41.98 g (0.259

- 52 -

mol) of 1,1'-carbonyldiimidazole in 250 mL of dry THF was stirred under argon at 55°C for 24 hours. The solvent was removed on a rotary evaporator and the residue was partitioned between 500 mL of ethyl acetate and 400 mL of water. The layers were separated and the aqueous phase was extracted once more with ethyl acetate. The combined ethyl acetate extracts were washed with 2 x 200 mL of 2% aqueous HCl, saturated aqueous NaHCO₃, and brine. Drying over MgSO₄, filtration, and removal of the solvent in vacuo provided 16.42 g of the title compound as a solid. Recrystallization from ethyl acetate-hexane afforded 12.97 g of analytically pure (±) 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as a white crystals. mp: 178-180°C. ¹H-NMR (CDCl₃): 0.85 (m, 2H), 0.94 (m, 2H), 1.40 (m, 1H), 6.81 (d, J = 8.5 Hz, 1H), 7.37 (dd, J = 2.5, 8.5 Hz, 1H), 7.49 (d, J = 2.5 Hz, 1H), 8.87 (br s, 1H).

Step C: 6-Chloro-1-(1S)-camphanoyl-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one

To a solution containing (±) 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (12.97 g, 0.041 mol), 4-dimethylaminopyridine (1.02 g, 0.0083 mol), and (-) camphanic acid chloride (14.22 g, 0.06556 mol) in 350 mL of dry dichloromethane, stirred under argon in an ice bath, was added triethylamine (22.84 mL, 0.164 mol). The cooling bath was removed and the reaction was allowed to proceed at room temperature. After 75 min. the reaction was judged complete by thin layer chromatography (SiO₂, 4% EtOAc in CHCl₃), and the solution was diluted with 500 mL of CHCl₃ then washed with 10% citric acid (2X), water (1X), and brine (1X). Drying (MgSO₄), filtration, and removal of the solvent in vacuo left a colorless foam. This material was triturated with 200 mL of boiling hexane. On cooling to room temperature the desired diastereomeric camphanate imide precipitated. The solid was collected on a frit, washed with a little cold hexanes and dried in vacuo to give 7.79g of 6-chloro-1-(1S)-camphanoyl-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as white crystals.

SUBSTITUTE SHEET

- 53 -

mp: 164-165°C. HPLC purity: 99.2% @ 254 nm. ¹H-NMR (CDCl₃):
δ 0.77 (s, 3H), 0.86-0.96 (m, 4H), 1.08 (s, 3H), 1.19 (s, 3H), 1.44 (m,
1H), 1.76 (m, 1H), 1.95 (m, 1H), 2.51 (m, 2H), 7.42 (dd, J = 2.4, 9.0 Hz,
1H), 7.63 (m, 2H).

Step D: (-) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-
dihydro-2H-3,1-benzoxazin-2-one (L-743,726, Compound
37.2)

6-chloro-1-(1S)-camphanoyl-4-cyclopropylethynyl-4-
trifluoromethyl-1,2-dihydro-4(H)-3,1-benzoxazin-2-one (7.50 g,
0.01512 mol) was dissolved in 150 mL of n-butanol at 60°C under an
atmosphere of argon. To this solution was added 10 mL of 1N HCl.
This solution was maintained at 60°C for 72h. The mixture was
neutralized with aqueous NaHCO₃ and the n-butanol was removed in
vacuo. The residue was dissolved in 150 mL of THF and treated with
50 mL of 2N LiOH for 3h at room temperature. This mixture was
diluted with ethyl acetate and washed with two portions of water and
one of brine. Drying (MgSO₄), filtration and removal of the solvent in
vacuo gave a white solid. This material was recrystallized from hot
hexane to give 3.43 g of (-) 6-chloro-4-cyclopropylethynyl-4-
trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as white
crystals., m.p. 131-132°C; [α]_D²⁰ = - 84.7° (CHCl₃, c=0.005 g mL⁻¹);
¹H-NMR (CDCl₃): δ 0.85 (m, 2H), 0.94 (m, 2H), 1.40 (m, 1H), 6.81
(d, J = 8.5 Hz, 1H), 7.37 (dd, J = 2.5, 8.5 Hz, 1H), 7.49 (d, J = 2.5 Hz,
1H), 8.87 (br s, 1H).

Step E: (+) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-
dihydro-2H-3,1-benzoxazin-2-one (L-743,725)

The mother liquors from Step C above were purified by
column chromatography on silica gel using 10% ethyl acetate in hexanes
as eluant. The pure, undesired diastereomer (a colorless foam) was
hydrolyzed according to Step D. The enantiomeric benzoxazinone, (+)
6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-
benzoxazin-2-one, was obtained as white crystals. m.p. 131-132°C;

SUBSTITUTE SHEET

- 54 -

$[\alpha]_D^{20} = + 84.4^\circ$ (CHCl_3 , $c=0.005 \text{ g mL}^{-1}$); $^1\text{H-NMR}$ (CDCl_3): δ 0.85 (m, 2H), 0.94 (m, 2H), 1.40 (m, 1H), 6.81 (d, $J = 8.5 \text{ Hz}$, 1H), 7.37 (dd, $J = 2.5, 8.5 \text{ Hz}$, 1H), 7.49 (d, $J = 2.5 \text{ Hz}$, 1H), 8.87 (br s, 1H).

5

REVERSE TRANSCRIPTASE ASSAY

The assay measures the incorporation of tritiated deoxyguanosine monophosphate by recombinant HIV reverse transcriptase (HIV RT_R) (or other RT) into acid-precipitable cDNA at the K_m values of dGTP and poly r(C)-oligo d(G)₁₂₋₁₈. The inhibitors of the present invention inhibit this incorporation.

The assays were carried out in 55 mM Tris (pH 8.2)-30 mM KCl-30 mM MgCl_2 -1 mM dithiothreitol-20 μg of rC:dG₁₂₋₁₈ (Pharmacia) per ml-8 mM [^3H]dGTP (New England Nuclear)-0.01% Triton X-100-50 mM ethylene glycol-bis(β -amino-ethyl ether)-N,N,N',N'-tetraacetic acid (EGTA)-1 mg of bovine serum albumin per ml. After 60 min of incubation at 37°C, acid-precipitable material was collected onto glass fiber filters by using a semiautomatic cell harvester. Bacterial cell extracts containing RT were diluted to within the linear range of the assay, and activity was determined in the presence and absence of inhibitor. Purified HIV-1 RT heterodimer produced in *E. coli* also served as a control. Results are determined as inhibitor concentration to give 50% inhibition (IC_{50} wt), in nanomoles/liter.

For the double mutant assay (dm), A17 RT was employed in the assay. A17 RT is resistant to various aminopyridones, as described in Nunberg, J.H. *et al.*, J. Virol. 65, 4887 (1991). Results are measured as IC_{50} dm in nanomoles/liter.

30

CELL SPREAD ASSAY

Inhibition of the spread of HIV in cell culture was measured according to Nunberg, J. H. *et al.*, J. Virol. 65, 4887 (1991). In this assay, MT-4 T-lymphoid cells were infected with HIV-1 (wild-type, unless otherwise indicated) by using a predetermined inoculum,

- 55 -

and cultures were incubated for 24h. At this time, $\leq 1\%$ of the cells were positive by indirect immunofluorescence. Cells were then extensively washed and distributed into 96-well culture dishes. Serial twofold dilutions of inhibitor were added to the wells, and cultures were continued for 3 additional days. At 4 days postinfection, 100% of the cells in control cultures were infected. HIV-1 p24 accumulation was directly correlated with virus spread. The cell culture inhibitory concentration was defined as the inhibitor concentration in nanomoles/liter which reduced the spread of infection by at least 95%, or CIC₉₅.

SUBSTITUTE SHEET

- 56 -

SUMMARY OF RESULTS FOR COMPOUND 37.2A. Reverse Transcriptase Assay and Cell Spread Assay:

5		<u>WT</u>	<u>K103N*</u>	<u>Y181C</u>	<u>DM</u>	<u>RT-2</u>
	IC ₅₀ (μ M)	0.002	0.030	0.008	0.085	80.8
10	CIC ₉₅ (μ M)	<0.006(N=2)	0.100	<0.025	0.400	N.D.

B. Pharmacological Data:

15	Rhesus: 1 mg kg ⁻¹ i.v.: t _{1/2} =210 min.	} O.B.=0.55 (A.U.C.)
	10 mg kg ⁻¹ p.o. (methocel): C _{max} =4.4 μ M @ 2h C _{24h} =1.1 μ M	

Protein Binding: 98.0% Normal Human Plasma (HPLC Method)

- 20 * Mutants K103N and Y181C are drug-resistant HIV-1 reverse transcriptases. DM is the double mutant, as discussed in the reverse transcriptase assay. RT-2 is the reverse transcriptase of HIV-2.

25 SYNERGISTIC EFFECTSA. Preparation of HIV-infected MT-4 cell Suspension

MT cells were infected at Day 0 at a concentration of 250,000 per ml with a 1:1000 dilution of HIV-1 strain IIIb stock (final 30 125 pg p24/ml; sufficient to yield \leq 1% infected cells on day 1 and 25-100% on day 4). Cells were infected and grown in the following medium: RPMI 1640 (Whittaker BioProducts), 10% inactivated fetal bovine serum, 4 mM glutamine (Gibco Labs) and 1:100 Penicillin-Streptomycin (Gibco Labs).

SUBSTITUTE SHEET

- 57 -

The mixture was incubated overnight at 37°C in 5% CO₂ atmosphere.

5 B. Treatment with Inhibitors

 A matrix of nanomolar range concentrations of the pairwise combinations (see Table S) was prepared. At Day 1, aliquots of 125 µl of inhibitors were added to equal volumes of HIV-infected MT-4 cells (50,000 per well) in a 96-well microtiter cell culture plate. Incubation was continued for 3 days at 37°C in 5% CO₂ atmosphere.

10 C. Measurement of Virus Spread

 Using a multichannel pipettor, the settled cells were resuspended and 125 µl harvested into a separate microtiter plate. The supernatant was assayed for HIV p24 antigen.

15 The concentration of HIV p24 antigen was measured by an enzyme immunoassay, described as follows. Aliquots of p24 antigen to be measured were added to microwells coated with a monoclonal antibody specific for HIV core antigen. The microwells were washed at this point, and at other appropriate steps that follow. Biotinylated HIV-specific antibody was then added, followed by conjugated strepavidin-horseradish peroxidase. A color reaction occurs from the added hydrogen peroxide and tetramethylbenzidine substrate. Color intensity is proportional to the concentration of HIV p24 antigen.

25 Calculation of Degree of Synergy

 Pairwise combinations of inhibitors (see Table 5) were found to exhibit markedly enhanced inhibition of virus spread, in comparison to each inhibitor alone, or in comparison to merely additive inhibition of each inhibitor. Thus, for example, the pairwise combination of 726 and AZT was found to exhibit markedly enhanced inhibition of virus spread, in comparison to 726 alone or AZT alone, or in comparison to the sum of 726 inhibition and AZT inhibition.

 This data was processed as follows:

- 58 -

fractional inhibitory concentration ratios (FIC) were calculated according to Elion, et. al. J. Biol. Chem., 208 477 (1954). The minimum sum of FICS, which is the maximum synergy, was determined for various pairwise combinations. Alternatively, an average sum of the FICS is calculated, which is the average synergy. See Table S. These results indicate substantial synergy in the inhibition of virus spread. The smaller the number, the greater the synergy.

TABLE S

<u>Pairwise Combinations*</u>	<u>Average Synergy</u>
726 + ddI	0.81
726 + AZT	0.62
726 + 524	0.65
726 + 524 + AZT	


524 is L-735,524. Other compounds are also defined in Table C above.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations, or modifications, as come within the scope of the following claims and its equivalents.

- 59 -

WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein:

X is halo,
 X^1 is trihalomethyl, or pentahaloethyl;
 Z is O;

R is


- (a) C_{1-8} alkyl, unsubstituted or substituted with A, and A is halo, C_{3-6} cycloalkyl, CN, hydroxy, C_{1-4} alkoxy, C_{2-4} alkynyl- C_{1-4} alkoxy, aryloxy, C_{1-4} alkylcarbonyl, nitro, di(C_{1-2} alkyl)amino, C_{1-4} alkylamino- C_{1-2} alkyl, heterocycle, or arylthio;
- (b) C_{2-4} alkenyl, unsubstituted or substituted with
 - (i) A, or
 - (ii) aryl, unsubstituted or substituted with A;
- (c) C_{2-5} alkynyl, unsubstituted or substituted with
 - (i) A, or
 - (ii) aryl, unsubstituted or substituted with A; or
- (d) C_{3-4} cycloalkyl, unsubstituted or substituted with
 - (i) A, or
 - (ii) aryl, unsubstituted or substituted with A,

or pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition useful for inhibiting HIV reverse transcription, comprising an effective amount of a compound of Formula II,

SUBSTITUTE SHEET

- 60 -



5

and a pharmaceutically acceptable carrier,
wherein

10

X is halo;
X¹ is trihalomethyl; pentahaloethyl; C₂₋₅ alkyl;
C₂₋₅ alkynyl;
C₃₋₅ cycloalkyl; or aryl;
Z is O or S;

15 R is

- (a) C₁₋₈ alkyl, unsubstituted or substituted with A, and A is halo, C₃₋₆ cycloalkyl, CN, hydroxy, C₁₋₄ alkoxy, C₂₋₄ alkynyl-C₁₋₄ alkoxy, aryloxy, C₁₋₄ alkylcarbonyl, nitro, di(C₁₋₂ alkyl)amino, C₁₋₄ alkylamino-C₁₋₂ alkyl, heterocycle, or arylthio;
- (b) C₂₋₄ alkenyl, unsubstituted or substituted with
- (i) A, or
- (ii) aryl, unsubstituted or substituted with A;
- (c) C₂₋₅ alkynyl, unsubstituted or substituted with
- (i) A, or
- (ii) aryl, unsubstituted or substituted with A; or
- (d) C₃₋₄ cycloalkyl, unsubstituted or substituted with
- (i) A, or
- (ii) aryl, unsubstituted or substituted with A,

30

or pharmaceutically acceptable salt thereof.

- 61 -

3. A compound, which is

(-) 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one,

5

(-) 6-chloro-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one,

(+/-) 6-chloro-4-(2-cyanophenyl)ethynyl-4-(1,1,1-trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one,

10

(+/-) 4-(1-chloro-1,1-difluoromethyl)-4-(2-phenylethynyl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one, or

15

(+/-) 4-(2-[dimethylaminomethyl]ethynyl)-4-trifluoromethyl-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one,

or a pharmaceutically acceptable salt thereof.

20

4. A method of inhibiting HIV reverse transcriptase, comprising administering to a mammal an effective amount of a compound of Formula I or II or of Claim 3.

25

5. A method of preventing infection of HIV, or of treating infection by HIV or of treating AIDS or ARC, comprising administering to a mammal an effective amount of a compound Formula I or Formula II or of Claim 3.

30

6. A pharmaceutical composition useful for inhibiting HIV reverse transcriptase, comprising an effective amount of a compound as in any of Claims 1, 2 or 3, and a pharmaceutically acceptable carrier.

- 62 -

7. A pharmaceutical composition useful for preventing or treating infection of HIV or for treating AIDS or ARC, comprising an effective amount of a compound of Formula I or Formula II or of Claim 3, and a pharmaceutically acceptable carrier.

8. A combination of a compound of Formula I or Formula II with a nucleoside analog having biological activity against HIV reverse transcriptase.

9. A synergistic combination of AIDS antiviral compounds, which is L-743,726 and L-735,524, and, optionally, one or more of the HIV inhibitors selected from the group consisting of L-697,661, AZT, ddI or ddC.

10. A synergistic combination of AIDS antiviral compounds, which is L-743,726 and one or more of the HIV inhibitors selected from the group consisting of L-697,661, AZT, ddI, or ddC.

11. A process for synthesizing (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726), comprising the steps of

- (a) providing a quantity of (+/-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-741,211);
- (b) condensing the compounds of step (a) with a resolving agent;
- (c) separating the resulting diastereomers;
- (d) removing the resolving agent modification to give desired compound.

12. The process of Claim 11, wherein the resolving agent is (-)-camphanyl chloride.

INTERNATIONAL SEARCH REPORT,

International Application No

PCT/US 93/07376

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D265/18 A61K31/535

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, A, 0 093 922 (DR. KARL THOMAE GMBH.) 16 November 1983	
A	US, A, 3 526 621 (L. BERNARDI ET AL.) 1 September 1970	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

9 November 1993

Date of mailing of the international search report

- 3. 12. 93

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

CHOULY, J

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 4,5 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0093922	16-11-83	DE-A- 3217012	10-11-83
		AU-B- 563453	09-07-87
		AU-A- 1426583	10-11-83
		CA-A- 1204744	20-05-86
		GB-A, B 2119382	16-11-83
		JP-A- 58203979	28-11-83
		SU-A- 1138025	30-01-85
		US-A- 4518597	21-05-85
US-A-3526621	01-09-70	BE-A- 702201	02-02-68
		BE-A- 704583	02-04-68
		DE-A, C 1695756	02-03-72
		DE-A, B, C 1695780	29-04-71
		FR-E- 93909	06-06-69
		FR-A- 1533010	
		GB-A- 1135899	
		NL-A- 6710332	05-02-68
		NL-A- 6713047	21-10-68
		CH-A- 478828	30-09-69
		FR-M- 6494	25-11-68

THIS PAGE BLANK (USPTO)